UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

The lancet oncology, 2013-03, Vol.14 (3), p.228-235

2013

Volltextzugriff (PDF)

Expression of luminal and basal cytokeratins in human breast carcinoma

The Journal of pathology, 2004-06, Vol.203 (2), p.661-671

2004

Volltextzugriff (PDF)

Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer

World journal of surgical oncology, 2011-09, Vol.9 (1), p.101-101, Article 101

2011

Volltextzugriff (PDF)

Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer

European journal of cancer (1990), 2021-03, Vol.145, p.19-28

2021

Volltextzugriff (PDF)

Protection from covid-19 at work: health and safety law is fit for purpose

BMJ (Online), 2021-12, Vol.375, p.n3087

2021

Volltextzugriff (PDF)

Was enough, and is enough, being done to protect the primary care workforce from COVID-19?

British journal of general practice, 2021-03, Vol.71 (704), p.100-101

2021

Volltextzugriff (PDF)

Reaffirming health and safety precautionary principles for COVID-19 in the UK

The Lancet (British edition), 2021-01, Vol.397 (10271), p.274-274

2021

Volltextzugriff (PDF)

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer

European journal of cancer (1990), 2018-05, Vol.94, p.206-215

2018

Volltextzugriff (PDF)

Successful management of elderly breast cancer patients treated without radiotherapy

World journal of surgical oncology, 2007-06, Vol.5 (1), p.62-62, Article 62

2007

Volltextzugriff (PDF)

High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

International journal of cancer, 2005-09, Vol.116 (3), p.340-350

2005

Volltextzugriff (PDF)

Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents

World journal of surgical oncology, 2006-07, Vol.4 (1), p.44-44, Article 44

2006

Volltextzugriff (PDF)

Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker

World journal of surgical oncology, 2010-05, Vol.8 (1), p.38-38, Article 38

2010

Volltextzugriff (PDF)

Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer

The Annals of pharmacotherapy, 2006-09, Vol.40 (9), p.1572-1583

2006

Volltextzugriff (PDF)

Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT)

Journal of evaluation in clinical practice, 2020-06, Vol.26 (3), p.893-902

2020

Volltextzugriff (PDF)

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long‐term effects based on sequential biopsies

International journal of cancer, 2016-01, Vol.138 (1), p.146-159

2016

Volltextzugriff (PDF)

Human Blood Autoantibodies in the Detection of Colorectal Cancer

PloS one, 2016-07, Vol.11 (7), p.e0156971-e0156971

2016

Volltextzugriff (PDF)

Abstract OT-09-05: A randomized, pre-surgical study to investigate the biological effects of AZD9833 doses in women with ER-positive HER2-negative primary breast cancer (SERENA-3)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-09-05-OT-09-05

2021

Volltextzugriff (PDF)

"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

World journal of surgical oncology, 2006-07, Vol.4 (1), p.40-40, Article 40

2006

Volltextzugriff (PDF)

Abstract P6-04-01: A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P6-P6-04-01

2020

Volltextzugriff (PDF)

Abstract P1-13-02: Visceral metastases from hormone receptor positive breast cancer are as sensitive to endocrine therapy as non-visceral metastases

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P1-P1-13-02

2015

Volltextzugriff (PDF)

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

Breast cancer research : BCR, 2013-03, Vol.15 (2), p.R18-R18, Article R18

2013

Volltextzugriff (PDF)

Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients

Breast cancer research : BCR, 2007-11, Vol.9 (6), p.R75-R75, Article R75

2007

Volltextzugriff (PDF)

Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ‘FIRST’ study

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.S6-S6-04

2015

Volltextzugriff (PDF)

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors

Breast cancer research : BCR, 2009-01, Vol.11 Suppl 3 (Suppl 3), p.S24-S24, Article S24

2009

Volltextzugriff (PDF)

Session 6 introduction

Breast cancer research : BCR, 2010-12, Vol.12 (Suppl 4), p.S15-S15, Article S15

2010

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Humans
(29)
Life Sciences & Biomedicine
(28)
Female
(21)
Breast Cancer
(17)
Oncology
(16)
Aged
(11)
Tumors
(11)
Breast Neoplasms - Pathology
(10)
Middle Aged
(10)
Prognosis
(9)
Breast Neoplasms - Drug Therapy
(8)
Adult
(7)
Aged, 80 And Over
(7)
Biological And Medical Sciences
(7)
Antineoplastic Agents, Hormonal - Therapeutic Use
(6)
Breast Neoplasms - Metabolism
(6)
Estradiol - Analogs & Derivatives
(6)
Gynecology. Andrology. Obstetrics
(6)
Mammary Gland Diseases
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

Expression of luminal and basal cytokeratins in human breast carcinoma

Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer

Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer

Protection from covid-19 at work: health and safety law is fit for purpose

Was enough, and is enough, being done to protect the primary care workforce from COVID-19?

Reaffirming health and safety precautionary principles for COVID-19 in the UK

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer

Successful management of elderly breast cancer patients treated without radiotherapy

High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents

Bony metastases from breast cancer - a study of foetal antigen 2 as a blood tumour marker

Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer

Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT)

Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long‐term effects based on sequential biopsies

Human Blood Autoantibodies in the Detection of Colorectal Cancer

Abstract OT-09-05: A randomized, pre-surgical study to investigate the biological effects of AZD9833 doses in women with ER-positive HER2-negative primary breast cancer (SERENA-3)

"Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer

Abstract P6-04-01: A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer

Abstract P1-13-02: Visceral metastases from hormone receptor positive breast cancer are as sensitive to endocrine therapy as non-visceral metastases

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer

Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients

Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ‘FIRST’ study

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors

Session 6 introduction

Suchergebnisse filtern